KR20200011627A - The composition for inhibting dissolution codycepin - Google Patents

Abstract

The present invention is a composition for inhibiting cordycepin decomposition, comprising cordycepin or cordycepin militaris and naringin. The ratio of cordycepin or cordycepin militaris and naringin is 1:2 to 1:16. The composition further comprises cyclodextrins. The composition is a cyclodextrin selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin, and hydroxypropyl-γ-cyclodextrin. In addition, the present invention provides a functional beverage composition, a functional food composition, and a pharmaceutical composition in which the efficacy duration is increased by inhibiting the decomposition of cordycepin or cordycepin militaris.

Description

The composition for inhibting dissolution codycepin}

The present invention is to provide a method for inhibiting the breakdown of cordycepin or cordycepin contained in Millipris cordyceps in vivo.

In addition, the present invention is to provide a composition comprising a component that inhibits the breakdown of cordycepin or cordycepin contained in millipris cordyceps in vivo.

In addition, the present invention includes a cordycepin or militia cordyceps, including cordycepin and cordycepin in addition to a component that inhibits the degradation in vivo to collect the components of the cordycepin or millitaris cordyceps It is to provide a composition that further inhibits the breakdown in vivo with the pin and the components that inhibit degradation in vivo.

Further, in the present invention, the present invention comprises a component that inhibits the breakdown of cordycepin and cordycepin contained in cordycepin or millitaris cordyceps in vivo, and a component for capturing them, thereby to cordycepin or millitaris cordyceps Increasing the efficacy duration of cordycepin and components that inhibit degradation in vivo by inhibiting the breakdown of cordycepin and cordycepin contained in cordycepin or militaris cordyceps in vivo To provide a functional beverage composition, a functional food composition and a pharmaceutical composition.

Cordyceps sinensis is a fungus that enters the body of insects in winter, absorbs nutrients while wintering, and grows into mushrooms in the body of dead insects in summer, and is classified as Ascomycota, Pyrenomycetes, It belongs to Clavicipitaceae, Cordyceps, and 100 genera and 300 species are known all over the world, including Korea, China and Japan. Among them, the Militaris cordyceps is a kind of Entomopathogenic fungi, mainly orange larvae or pupae, which form orange clubs. There are shaped follicles.

In relation to the efficacy on Cordyceps sinensis, the bioactive substance cordycepin is known as an active ingredient.

Cordycepin, represented by the following formula (1), is a 3-deoxyadenosine-based natural compound with a molecular weight of 251.2 and has been studied for its pharmacological activity since it was first discovered in 1950 by Cunningham et al. By doing so, antibacterial, antifungal, antiviral effects, platelet aggregation inhibitory effects and anticancer effects through immune enhancement are well known.

[Formula 1]

In particular, the fruiting body of Militaris cordyceps is relatively high in cordycepin, which is known to protect the lungs and strengthen the kidneys, and is widely recognized for its effects as a tonic and treatment for tuberculosis and jaundice. It is used as an expensive herbal medicine used for body control and medicine. In particular, antiviral and immune enhancing components have been known in recent years, and has been shown to be effective in pulmonary tuberculosis, chronic cough, asthma, anemia, male sexual dysfunction, hypertension. In addition, since the anti-cancer component ergosterol peroxide in Militaris cordyceps was identified in Korea, it is also known to be effective in relieving stress, and thus it is considered that the field of application will be further expanded.

Adenosine deaminase (ADA, EC 3.5.4.4) is commonly found in plants, bacteria, mammals, and especially in the human body, in the brain, heart, small intestine, and large intestine, where ADA is either adenosine or It is responsible for the enzymatic action of hydrolyzing cordycepin to metabolize it to inosine.

Scheme 1

ADA is present not only in red blood cells but also in lymphocytes and white blood cells, and plays an important role in showing immune function. Therefore, ADA deficiency weakens immune function and makes it vulnerable to disease invasion.

On the other hand, cordycepin (3'-deoxyadenosine) is a derivative of adenosine (2'-deoxyadenosine), because its structure is similar and can be easily metabolized by ADA, so if the half-life of cordycepin can be increased by inhibiting ADA You will have plenty of time to work in this body.

For this reason, many researchers have developed ADA inhibitors and reported deoxycoformycin (pentostatin) and erythro-9- (2-hydroxy-3-nonyl) adenine (EHNA), but their effects are so strong that they completely block the action of ADA. As a result of various limitations such as hematuria, leukopenia, thrombocytopenia, anemia, and the like, it is used only for diseases such as leukemia. Therefore, development of a weak toxic natural product ADA inhibitor is being promoted.

On the other hand, the present invention relates to a composition for inhibiting cordycepin and naringin degradation, further comprising cyclodextrin (CD; cyclodextrin), wherein the composition is a cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, At least one selected from hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, and the like.

In one aspect, the present specification is to provide a method for producing a nano-particle sized fucoxanthin micropowder collected with cyclodextrin to chemically stabilize the composition of the cordycepin and naringin degradation inhibitory and to increase the solubility and bioavailability do.

Cyclodextrins are cyclic substances in which D-glucopyranose is circularly bound by α-1,4-glucoside bonds, which are white crystals or crystalline powder, odorless and slightly sweet. Depending on the degree of polymerization of linked D-glucose, α-CD (6), β-CD (7), γ-CD (8) and the like are present and 9-10 are also known. Cyclodextrin is composed of a circular donut structure and has a unique characteristic of having hydrophobicity inside and hydrophilicity outside, and having a clathrate function and making a stable emulsion through emulsification and homogenization of various oily substances.

In an exemplary embodiment, the cyclodextrin may be preferably β-cyclodextrin or hydroxypropyl-β-cyclodextrin in view of the collection efficiency of cordycepin and naringin degradation inhibitory composition.

Cordycepin, a major active ingredient of Militaris cordyceps, is decomposed into inosine within a few seconds to several minutes by adenosine deaminase (ADA) in a human or animal body, thereby failing to properly perform various pharmacological functions.

The present invention is intended to solve this drawback, and to improve the drawback that the cordycepin is not properly exerted in various pharmacological functions by the degradation of inosine by ADA in vivo in humans or animals.

The present invention, the main active ingredient of Militaris Cordyceps sinensis is to improve the disadvantage that in the human or animal by adenosine deaminase (ADA) to inosine within a few seconds to several minutes to properly exert various pharmacological functions Method for inhibiting cordycepin in vivo by adding a weakly toxic natural product ADA inhibitor to cordycepin or cordycepin (hereinafter, referred to as 'militaris cordyceps cordycepin') included in cordycepin or militaris cordyceps. To provide.

The present invention also provides a composition comprising a natural ADA inhibitor having a weak toxicity that inhibits the breakdown of cordycepin and cordycepin, and the present invention also has a mild toxicity that inhibits the degradation of Militaris Cordyceps sinensis cordycepin. It is to provide a composition comprising a natural product ADA inhibitor.

In addition, the present invention suppresses the decomposition of cordycepin or millitaris cordyceps cordycepin by adding a natural ADA inhibitor, a weak toxicity, industrially, functional beverage composition, functional food composition and the efficacy duration of millitaris cordyceps It is to provide a pharmaceutical composition.

The present inventors have searched and tested a weakly toxic natural product ADA inhibitor that inhibits the degradation of cordycepin or millitaris cordyceps cordycepin, and as a result, the naringin, kaempferol, quercetin, myricetin, naringenin, and the like were selected as candidates. As a result of the experiment, finally confirming the important fact that naringin is the best effect of inhibiting the decomposition of cordycepin or millitaris cordyceps cordycepin among these candidates, and revealed the concentration to complete the present invention will be.

Naringin represented by the following Chemical Formula 2 is naringenin-7-rhamnoglucoside, and the molecular formula is C ₂₇ H ₃₂ O ₁₄ : molecular weight is 580.54, which is the glucoside of the highly crystalline colorless crystal flavonon. Naringin is a natural product belonging to citrus fruits and can be extracted from orange, lemon, lime, grafe fruit, citrus aurantium, citrus grandis, citrus junos, citrus unshiu marcor, citrus konokuni tanaka, etc.

Naringin has been known to have antioxidant, anti-inflammatory, anti-cancer, anti-allergic, and anti-diabetic effects. Recently, naringin has been known to have an inhibitory effect on angiogenesis.

[Formula 2]

The inventors of the present invention found that naringin is capable of hydrogen bonding with the active site of ADA and the surface of ADA protein as a substance having a high molecular weight, and thus acts as a powerful ADA inhibitor, thereby inhibiting the decomposition of cordycepin or millitaris cordyceps sinensis cordycepin by ADA. Since it can be used in combination with cordycepin or millitaris cordyceps cordycepin, it is invented that can exhibit long-term effects at high concentration without toxicity.

The present invention provides a method of inhibiting the breakdown of cordycepin in vivo by adding naringin to cordycepin or millitaris cordyceps sinensis cordycepin.

In another aspect, the present invention provides a composition comprising nadiazine to inhibit the breakdown of cordycepin and cordycepin, and provides a composition comprising Militaris Cordyceps sinensis cordycepin and naringin inhibiting its degradation.

In another aspect, the present invention provides a composition comprising nadirzin, which is a component that inhibits the breakdown of cordycepin and cordycepin contained in cordycepin or militaris cordyceps in vivo, and a cyclodextrin that traps them.

According to the present invention, a) the ratio of the molarity (M) of cordycepin or millicari cordyceps cordycepin to b) the molarity (M) of naringin, ie, 1: 1 or less when a: b is 1: 2 or more Degradation of cordycepin was inhibited by 10 times or more than in the concentration of residual cordycepin was shown to have an effect of 10 times or more, and it has been shown to have a critical significance, preferably 1: 2 to 16, more preferably 1 : 4-16, most preferably 1: 8-16.

In addition, the present invention provides a functional beverage composition, a functional food composition, and a pharmaceutical composition which inhibit the decomposition of cordycepin or millitaris cordyceps herbaceous cordycepin by adding naringin, thereby increasing the efficacy duration of millitaris cordyceps.

Naringin can be extracted from citrus fruits such as mandarin orange, sugary citron, tangerine, orange, lemon, grapefruit or citron, or can be prepared by known synthetic methods. Naringin is particularly contained in grapefruit, sugary citron and citron.

The pharmaceutical composition may be prepared by adding naringin as a decomposition inhibitor of cordycepin to cordycepin or millitaris cordyceps cordycepin, adding cyclodextrins that collect them, and mixing with a pharmaceutically acceptable carrier. The pharmaceutical composition may further include excipients, disintegrants, sweeteners, lubricants, flavoring agents and the like that are commonly used, tablets, capsules, powders, granules, suspensions, emulsifiers, syrups, solutions by conventional methods Or in dosage unit forms or as multi-dose pharmaceutical preparations such as parenteral preparations.

Cordycepin disintegration inhibiting composition which adds naringin to cordycepin or militaris cordycepin cordycepin as an active ingredient and cyclodextrin as a collecting agent may be parenterally or orally administered as desired. Naringin may be administered in one to several portions so that naringin is administered in an amount of 0.5 mg to 100 mg, preferably 2 to 20 mg per kg of body weight per day. Dosage levels for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of the disease, and the like.

Cordycepin or disintegration inhibiting composition of cordycepin, which is added to narcazine as an active ingredient and cyclodextrin as a collecting agent, may be added to food or beverage for the same purpose. Foods to which naringin can be added for the development of health functional foods include, for example, various foods, meats, beverages, chocolates, snacks, confections, pizzas, ramen, other noodles, gums, ice creams, alcoholic beverages, vitamin complexes, Dietary supplements;

Health functional food using the composition according to the present invention may be provided in various forms, such as health drinks, functional supplements, tea, confectionary or pharmaceuticals.

The composition according to the present invention may include components that are commonly added during food preparation for use as a food composition. For example proteins, fats, nutrients, seasonings and flavoring agents. As the flavoring agent, natural flavoring agents (tautin, stevia extract) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

Formulations such as pills, granules, beverages, tablets, capsules and the like can be prepared using the compositions according to the invention, in which case additives can be added to prepare each formulation.

In order to use the present invention as a pharmaceutical composition, it may be prepared by a method known in the pharmaceutical art, and may be mixed with itself or a pharmaceutically acceptable carrier, excipient, diluent, etc., to powder, granule, tablet, capsulant or It may be prepared and used in the form of an injection. They can also be administered orally or parenterally.

Each can be formulated and used in the form of powders, granules, tablets, capsulants, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods. Carriers, excipients and diluents that may be included include lactose, textose, sucrose, sorbitol, mannitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl Pyrrolidone, water, methyl hydride, oxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsulants, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. Are mixed to prepare. In addition to simple excipients, lubricants such as magnesium sterate talc may also be used.

Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and various excipients, such as water and liquid paraffin, which are commonly used simple diluents, may include, for example, wetting agents, sweeteners, fragrances, and preservatives. .

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.

As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The effective dosage of the composition according to the present invention may be appropriately selected depending on the absorption of the active ingredient in the body, the rate of water activation and excretion, the age, sex and condition of the patient, the severity of the disease to be treated and the like.

The composition according to the invention can be used in livestock feed and in each case can be prepared using additives or additives that are acceptable in livestock feed.

In order to use the composition according to the present invention as an active ingredient of a cosmetic composition, the components included in the cosmetic composition include components commonly used in cosmetic compositions in addition to the red ginseng extract. And conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings and carriers.

Cosmetics according to the present invention may be prepared in any formulations conventionally made in the art. For example, they may be formulated as solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations and sprays, but are not limited thereto. no.

More specifically, it may be prepared in the form of a flexible lotion, nourishing cream, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol chiba esters, polyethylene glycols or sorbitan may be used.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether. Sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of spray, additionally chlorofluorohydrocarbon, propane Propellants such as butane or dimethyl ether.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

Cosmetics containing the composition according to the present invention as an active ingredient may include a composition selected from the group consisting of water-soluble vitamins, fat-soluble vitamins, sphingolipids, polymer polysaccharides, polymer peptides.

As the water-soluble vitamin, any compound that can be formulated in cosmetics can be used, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamini B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H and the like. And salts thereof (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) can also be used in the present invention. Can be included. The water-soluble vitamin can be obtained by conventional methods such as microbial transformation, purification of microorganism culture, enzyme or chemical synthesis.

Any fat-soluble vitamin can be used as long as it is formulated in cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (DL-alphatocopherol, D-alpha tocopherol) and the like and derivatives thereof (palmitinic acid) Corbin, ascorbate stearate, ascorbine dipalmitate, acetic acid DL-alphatocopherol, nicotinic acid, DL-alphatocopherol, vitamin E, DL = pantotenyl alcohol, pantotenylethyl ether, etc.) are also used in the present invention. Included in vitamins. Fat-soluble vitamins can be obtained by conventional methods such as microbial transformation, microbial culture, purification, enzyme or chemical synthesis.

The cosmetic of the present invention may be blended with the above essential ingredients, if necessary, with other ingredients normally formulated into cosmetics. Other ingredients that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation promoting agents, cooling agents, limiting agents, purified water and the like.

Moreover, the compounding component which may be added other than it is not limited above, All the said components can be mix | blended within the range which does not impair the objective and effect of this invention.

Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples. However, the following Examples are only for illustrating the present invention, but the scope of the present invention is not limited to these.

Cordycepin or millitaris cordyceps according to the present invention is a method and composition for inhibiting the breakdown of cordycepin and naringin in vivo by adding naringin to cordycepin and adding cyclodextrin as a collecting agent, cordycepin or millitaris cordyceps In addition to inhibiting the breakdown of cordycepin, it also inhibits the breakdown of naringin, thereby showing an effect of greatly increasing the efficacy duration of cordycepin or militaris cordyceps cordycepin.

1 is a calibration curve of standard cordycepin and millitaris cordyceps cordycepin.
2 is a graph showing the results of inhibition of degradation by concentration of naringin against 50 μM cordycepin.

Hereinafter, the present invention will be described in more detail.

The terms or words used in this specification and claims are not to be construed as limiting in their usual or dictionary meanings, and that the inventor may properly define the concept of terms in order to best describe his or her invention. Based on the principle, it should be interpreted as meaning and concept corresponding to the technical idea of the present invention.

Therefore, the matters described in the experimental examples and drawings described herein are only the most preferred examples of the present invention and do not represent all of the technical idea of the present invention, and various equivalents that may be substituted for them at the time of the present application and It should be understood that there may be variations.

Hereinafter, the present invention will be described in more detail.

Example

5-10 ml of blood was collected from the heart of rats using Vacutainer (BD), and 6 ml of blood and 6 ml of stop solution (200 μM dipyridamole and 10 μM theophylline mixture) were reacted at room temperature for 30 minutes. Thereafter, the mixed solution of blood and stop solution was mixed with naringin (25, 50, 100, 200, 400, 800 μM) and 50 μl each, and reacted for 5 minutes in a 37 ° C. water bath. Naringin was dissolved in 2% ethanol at a concentration of 1 mg / ml and diluted again using 2% ethanol and used in the experiment. After that, using a refrigerated centrifuge maintained at 4 ℃ centrifuged for 10 minutes at a rate of 3,000g to recover only the supernatant as a plasma component. 300 μl of plasma and 300 μl of cordycepin (sigma) or Cordyceps diluent were mixed and centrifuged in a microcentrifuge. Then, the reaction was stopped for 2 minutes in a 37 ° C. waterbath and stopped on ice. Thereafter, 1200μl of acetonitril (ACN) and 600μl of the finished sample were mixed, followed by reaction at -70 ° C for 30 minutes to precipitate proteins. The protein precipitated sample was dissolved in ice again, centrifuged at 3,000 g for 30 minutes, and the supernatant was filtered with a 0.2 μm filter and measured by Waters UPLC.

1-1: Experimental Animal

Experimental animals used in the above examples were maintained in male rats (SD rat, Kotech, Korea) weighing 250-300 g at room temperature of 25 ± 2 ° C, humidity 50 ± 10%, and day and night cycles for 12 hours each. Feed and water were raised in a controlled environment so that they could be freely consumed.

1-2: Reagents and Materials

Reagents and materials used in the above examples are as follows.

end. Stop solution

Dipyridamole (sigma) was dissolved in Ethyl Alcohol (Duksan, GR grade) to a concentration of 40 mM. Theophyline (sigma) was dissolved in 0.9% NaCl aqueous solution to a concentration of 2 mM. Then, Dipyridamole and Therophyline were diluted in 0.9% aqueous NaCl solution to 400 μM and 20 μM, respectively. The mixture of the two solutions was used as a stop solution.

I. Naringin solution

Naringin (sigma) was dissolved in 0.9% NaCl aqueous solution to a concentration of 1 mM and dissolved in a water bath for 70 minutes in a 70 ℃ water bath. Because the crystals form when the temperature of the solution decreases, the mixture is dissolved by boiling in a 70 ℃ water bath before use, and then diluted by lowering the temperature to 37 ℃.

All. Standard Cordycepin Solution

The standard Cordycepin (coded cepin, purchased from sigma) was labeled with the standard cordycepin to distinguish it from Militaris cordyceps cordycepin), dissolved in 1M NH ₄ OH (sigma) to make 10 mg / ml, and made stock as needed. Dilute to 0.9% NaCl aqueous solution and use.

la. Militaris Cordyceps Cordycepin Solution

Millitaris Cordyceps sinensis cordycepin solution used in the experiment was diluted in distilled water (DW) to a concentration of 10 mg / ml, then bathed in a water bath at 80 ° C. for 20 minutes, mixed by vortexing for 30 seconds, and completely dissolved in 0.4 μm filter. It was used after filtering with (Millipore). Cordyepin content was analyzed using UPLC equipment from Waters, and UPLC BEH column 18 column was used for the analysis. The mobile phase used was 0.5 mM acetic acid (Junsei) and Acetonitrile (Duksan). In the UPLC analysis, Cordyceps sinensis extract was prepared in the same manner, and the average value measured was used as the amount of cordycepin included in the Militaris cordyceps extract.

hemp. Cyclodextrin

Cyclodextrin is at least one selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin It was used, purchased from Sigma.

Experimental Example 1: Calibration curve measurement of cordycepin and millitaris cordyceps sinensis cordycepin

In the blood, cordycepin is broken down in seconds to minutes and metabolized to inosine. Therefore, since the accurate concentration measurement of cordycepin is essential, the concentration of standard cordycepin was measured using UPLC of Waters, and in addition, the concentration of millitaris cordyceps sinensis cordycepin was measured. Experimental results were confirmed to show a correlation coefficient of 0.999 in the concentration range of 25 ~ 200 μg / ml as shown in Table 1 and Figure 1 below.

cordycepin concentration UPLC measurements Standard Cordycepin 25 μg / ml 1546052.967306 Militaris Cordyceps Cordycepin 25 μg / ml 1544564.310463 Standard Cordycepin 50 μg / ml 3098455.889420 Militaris Cordyceps Cordycepin 50 μg / ml 3091452.485755 Standard Cordycepin 100 μg / ml 6095927.482388 Militaris Cordyceps Cordycepin 100 μg / ml 6100922.530967 Standard Cordycepin 200 μg / ml 10597802.879015 Militaris Cordyceps Cordycepin 200 μg / ml 10605547.250057

Experimental Example 2 Measurement of Naringin Concentration to Inhibit Decomposition of Cordycepin

In order to measure the concentration of naringin that can effectively inhibit the breakdown of cordycepin, the concentration of naringin was treated from 25 μM to 800 μM when the concentration of millitaris cordyceps sinensis cordycepin was 50 μM. The concentration was measured.

As shown in Table 2 and FIG. 2, when the concentration of naringin is 50 μM or less, which is 1 times the concentration of millitaris cordyceps sinensis cordycepin, it is 0.18 μg / ml or less, which is similar to an untreated group, by not inhibiting the decomposition of cordycepin. It was measured at very low concentrations.

The concentration of residual cordycepin is measured at a very high concentration of 1.81 μg / ml or more, since the degradation of cordycepin is rapidly suppressed after 100 μM, the concentration of naringin is twice that of millitaris cordyceps cordycepin. Was measured.

That is, when the concentration of naringazine was 100 μM, the concentration increased rapidly to 1.81 μg / ml, which is 10 times (1000%) or more, compared to 0.18, which is the residual cordycepin concentration when the concentration of naringazine is 50 μM.

In addition, from 200 μM or more corresponding to four times the concentration of millitaris cordyceps cordycepin, the decomposition of cordycepin was further suppressed, and thus the concentration of residual cordycepin measured was increased more rapidly.

In addition, from 400 μM or more corresponding to 8 times the concentration of millitaris cordyceps cordycepin, the decomposition of cordycepin was further suppressed, and thus the concentration of residual cordycepin measured was increased more rapidly.

On the other hand, the standard cordycepin showed the same tendency as that of Militaris cordyceps, but the inhibition of degradation was slightly lowered, so that the concentration of residual cordycepin was slightly lowered. .

Naringin Treatment Concentration  Residual Cordycepin Average Concentration  0 μM 0.16 μg / ml 25 μM 0.17 μg / ml 50 μM 0.18 μg / ml 100 μM 1.81 μg / ml 200 μM 4.31 μg / ml 400 μM 8.11 μg / ml 800 μM 8.62 μg / ml

Claims (6)

a) cordycepin or millitaris cordyceps cordycepin; And
b) naringin;
As a composition for inhibiting decomposition of cordycepin comprising:
a) cordycepin or millitaris cordyceps cordycepin: b) a composition for inhibiting cordycepin degradation, wherein the ratio of naringin is 1: 2 to 16,
A composition for inhibiting cordycepin degradation, further comprising cyclodextrin.
The composition for inhibiting cordycepin degradation according to claim 1, wherein the ratio of a) cordycepin or millitaris cordyceps cordycepin: b) naringin is 1: 4 to 16.
The method of claim 2, wherein a) cordycepin or millitaris cordyceps cordycepin: b) nasal gin ratio of 1: 8 to 16, the composition for inhibiting cordycepin degradation.
The method of claim 1, wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclo Cordycepin degradation inhibitory composition, characterized in that at least one selected from dextrin.
Functional food composition comprising a composition for inhibiting cordycepin degradation of any one of claims 1 to 4.
Functional beverage composition comprising a composition for inhibiting cordycepin degradation of any one of claims 1 to 4.

Images